NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $7 | $3 | $6 | $1 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $2 | $2 | $2 |
| Total Curr. Assets | $12 | $5 | $7 | $3 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $1 | $0 | $0 | $0 |
| Intangibles | $2 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $3 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $15 | $5 | $8 | $4 |
| Liabilities | – | – | – | – |
| Payables | $4 | $4 | $4 | $4 |
| Short-Term Debt | $0 | $10 | $8 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $36 | $27 | $20 | $16 |
| Total Curr. Liab. | $41 | $40 | $33 | $22 |
| LT Debt | $0 | $0 | $0 | $5 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $5 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $41 | $40 | $33 | $27 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$307 | -$301 | -$284 | -$278 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $281 | $266 | $259 | $255 |
| Total Equity | -$26 | -$36 | -$25 | -$23 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $15 | $5 | $8 | $4 |
| Net Debt | -$7 | $7 | $3 | $5 |